PSMB7 and chronic rhinosinusitis with nasal polyps: In the remaining three patients out of the eight, even affected by CRSwNP, biologics were administered (Omalizumab, Benralizumab and Mepolizumab) mainly for their SEA as add on therapy with inhaled corticosteroids (ICS) with or without long-acting beta 2-adrenergic agonists.